{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:54:44Z","timestamp":1794862484801,"version":"4.9.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the paucity of human-relevant models for target discovery and compound screening. Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different triggers: free fatty acid loading, interindividual genetic variability (PNPLA3 I148M) and monogenic lipid disorders (<jats:italic>APOB<\/jats:italic> and <jats:italic>MTTP<\/jats:italic> mutations). Screening of drug candidates revealed compounds effective at resolving steatosis. Mechanistic evaluation of effective drugs uncovered repression of de novo lipogenesis as the convergent molecular pathway. We present FatTracer, a CRISPR screening platform to identify steatosis modulators and putative targets using <jats:italic>APOB<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> and <jats:italic>MTTP<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> organoids. From a screen targeting 35\u2009genes implicated in lipid metabolism and\/or NAFLD risk, FADS2 (fatty acid desaturase\u20092) emerged as an important determinant of hepatic steatosis. Enhancement of FADS2 expression increases polyunsaturated fatty acid abundancy which, in turn, reduces de novo lipogenesis. These organoid models facilitate study of steatosis etiology and drug targets.<\/jats:p>","DOI":"10.1038\/s41587-023-01680-4","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T17:03:30Z","timestamp":1677171810000},"page":"1567-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":230,"title":["Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis"],"prefix":"10.1038","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1159-5946","authenticated-orcid":false,"given":"Delilah","family":"Hendriks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2924-3279","authenticated-orcid":false,"given":"Jos F.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karien","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten H.","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0741-7071","authenticated-orcid":false,"given":"L\u00e9a","family":"Luciana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Massalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"L\u00f3pez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2964-5684","authenticated-orcid":false,"given":"Peter J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Rodr\u00edguez-Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-2803","authenticated-orcid":false,"given":"Susana","family":"Chuva de Sousa Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-4187","authenticated-orcid":false,"given":"Benedetta","family":"Artegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-5582","authenticated-orcid":false,"given":"Hans","family":"Clevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"1680_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"1680_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan, N., H\u00e4ring, H.-U. & Cusi, K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 7, 313\u2013324 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1680_CR4","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69, 2672\u20132682 (2019).","journal-title":"Hepatology"},{"key":"1680_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","volume":"17","author":"M Eslam","year":"2020","unstructured":"Eslam, M. & George, J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat. Rev. Gastroenterol. Hepatol. 17, 40\u201352 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1680_CR6","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461\u20131465 (2008).","journal-title":"Nat. Genet."},{"key":"1680_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1756283X11430859","volume":"5","author":"JM Kneeman","year":"2012","unstructured":"Kneeman, J. M., Misdraji, J. & Corey, K. E. Secondary causes of nonalcoholic fatty liver disease. Therap. Adv. Gastroenterol. 5, 199\u2013207 (2012).","journal-title":"Therap. Adv. Gastroenterol."},{"key":"1680_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jhep.2021.01.045","volume":"74","author":"R Liebe","year":"2021","unstructured":"Liebe, R. et al. Diagnosis and management of secondary causes of steatohepatitis. J. Hepatol. 74, 1455\u20131471 (2021).","journal-title":"J. Hepatol."},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOL.0000000000000072","volume":"25","author":"FK Welty","year":"2014","unstructured":"Welty, F. K. Hypobetalipoproteinemia and abetalipoproteinemia. Curr. Opin. Lipidol. 25, 161\u2013168 (2014).","journal-title":"Curr. Opin. Lipidol."},{"key":"1680_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0022-2275(20)39976-4","volume":"34","author":"M Linton","year":"1993","unstructured":"Linton, M., Farese, R. & Young, S. Familial hypobetalipoproteinemia. J. Lipid Res. 34, 521\u2013541 (1993).","journal-title":"J. Lipid Res."},{"key":"1680_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-19","volume":"3","author":"R Zamel","year":"2008","unstructured":"Zamel, R., Khan, R., Pollex, R. L. & Hegele, R. A. Abetalipoproteinemia: two case reports and literature review. Orphanet J. Rare Dis. 3, 19 (2008).","journal-title":"Orphanet J. Rare Dis."},{"key":"1680_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. Non-alcoholic fatty liver disease \u2013 a global public health perspective. J. Hepatol. 70, 531\u2013544 (2019).","journal-title":"J. Hepatol."},{"key":"1680_CR13","first-page":"501","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard, A. FDA rejects NASH drug. Nat. Rev. Drug Discov. 19, 501 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","volume":"18","author":"R Vuppalanchi","year":"2021","unstructured":"Vuppalanchi, R., Noureddin, M., Alkhouri, N. & Sanyal, A. J. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 18, 373\u2013392 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1680_CR15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","volume":"71","author":"J-F Dufour","year":"2022","unstructured":"Dufour, J.-F. et al. Current therapies and new developments in NASH. Gut 71, 2123\u20132134 (2022).","journal-title":"Gut"},{"key":"1680_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","volume":"18","author":"M Masoodi","year":"2021","unstructured":"Masoodi, M. et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat. Rev. Gastroenterol. Hepatol. 18, 835\u2013856 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1680_CR17","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/nu9101072","volume":"9","author":"M van Herck","year":"2017","unstructured":"van Herck, M., Vonghia, L. & Francque, S. Animal models of nonalcoholic fatty liver disease\u2014a starter\u2019s guide. Nutrients 9, 1072 (2017).","journal-title":"Nutrients"},{"key":"1680_CR18","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1053\/j.gastro.2020.06.010","volume":"159","author":"MNB Ramli","year":"2020","unstructured":"Ramli, M. N. B. et al. Human pluripotent stem cell-derived organoids as models of liver disease. Gastroenterology 159, 1471\u20131486 (2020).","journal-title":"Gastroenterology"},{"key":"1680_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cmet.2019.06.017","volume":"30","author":"A Collin de l\u2019Hortet","year":"2019","unstructured":"Collin de l\u2019Hortet, A. et al. Generation of human fatty livers using custom-engineered induced pluripotent stem cells with modifiable SIRT1 metabolism. Cell Metab. 30, 385\u2013401 (2019).","journal-title":"Cell Metab."},{"key":"1680_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.cmet.2019.05.007","volume":"30","author":"R Ouchi","year":"2019","unstructured":"Ouchi, R. et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab. 30, 374\u2013384 (2019).","journal-title":"Cell Metab."},{"key":"1680_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32722-6","volume":"8","author":"M Kozyra","year":"2018","unstructured":"Kozyra, M. et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Sci. Rep. 8, 14297 (2018).","journal-title":"Sci. Rep."},{"key":"1680_CR22","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1002\/hep.32063","volume":"74","author":"SG Tilson","year":"2021","unstructured":"Tilson, S. G. et al. Modelling PNPLA3\u2010associated non\u2010alcoholic fatty liver disease using human induced pluripotent stem cells. Hepatology 74, 2998\u20133017 (2021).","journal-title":"Hepatology"},{"key":"1680_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.cell.2018.11.013","volume":"175","author":"H Hu","year":"2018","unstructured":"Hu, H. et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell 175, 1591\u20131606 (2018).","journal-title":"Cell"},{"key":"1680_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41596-020-00411-2","volume":"16","author":"D Hendriks","year":"2021","unstructured":"Hendriks, D., Artegiani, B., Hu, H., Chuva de Sousa Lopes, S. & Clevers, H. Establishment of human fetal hepatocyte organoids and CRISPR\u2013Cas9-based gene knockin and knockout in organoid cultures from human liver. Nat. Protoc. 16, 182\u2013217 (2021).","journal-title":"Nat. Protoc."},{"key":"1680_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41556-020-0472-5","volume":"22","author":"B Artegiani","year":"2020","unstructured":"Artegiani, B. et al. Fast and efficient generation of knock-in human organoids using homology-independent CRISPR\u2013Cas9 precision genome editing. Nat. Cell Biol. 22, 321\u2013331 (2020).","journal-title":"Nat. Cell Biol."},{"key":"1680_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.stem.2020.10.014","volume":"27","author":"D Hendriks","year":"2020","unstructured":"Hendriks, D., Clevers, H. & Artegiani, B. CRISPR-Cas tools and their application in genetic engineering of human stem cells and organoids. Cell Stem Cell 27, 705\u2013731 (2020).","journal-title":"Cell Stem Cell"},{"key":"1680_CR27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly, K. L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343\u20131351 (2005).","journal-title":"J. Clin. Invest."},{"key":"1680_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep05832","volume":"4","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci. Rep. 4, 5832 (2014).","journal-title":"Sci. Rep."},{"key":"1680_CR29","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1194\/jlr.M009449","volume":"51","author":"O Quehenberger","year":"2010","unstructured":"Quehenberger, O. et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51, 3299\u20133305 (2010).","journal-title":"J. Lipid Res."},{"key":"1680_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1055\/s-0028-1091980","volume":"28","author":"H Malhi","year":"2008","unstructured":"Malhi, H. & Gores, G. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 28, 360\u2013369 (2008).","journal-title":"Semin. Liver Dis."},{"key":"1680_CR31","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1172\/JCI65179","volume":"122","author":"JZ Li","year":"2012","unstructured":"Li, J. Z. et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin. Invest. 122, 4130\u20134144 (2012).","journal-title":"J. Clin. Invest."},{"key":"1680_CR32","doi-asserted-by":"publisher","first-page":"111321","DOI":"10.1016\/j.celrep.2022.111321","volume":"40","author":"M Kabbani","year":"2022","unstructured":"Kabbani, M. et al. Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice. Cell Rep. 40, 111321 (2022).","journal-title":"Cell Rep."},{"key":"1680_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"1680_CR34","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.1073\/pnas.1901974116","volume":"116","author":"S BasuRay","year":"2019","unstructured":"BasuRay, S., Wang, Y., Smagris, E., Cohen, J. C. & Hobbs, H. H. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc. Natl Acad. Sci. USA 116, 9521\u20139526 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1680_CR35","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jhep.2012.07.030","volume":"57","author":"C Pirazzi","year":"2012","unstructured":"Pirazzi, C. et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J. Hepatol. 57, 1276\u20131282 (2012).","journal-title":"J. Hepatol."},{"key":"1680_CR36","doi-asserted-by":"publisher","first-page":"e127902","DOI":"10.1172\/jci.insight.127902","volume":"4","author":"PK Luukkonen","year":"2019","unstructured":"Luukkonen, P. K. et al. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight 4, e127902 (2019).","journal-title":"JCI Insight"},{"key":"1680_CR37","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/hep.23812","volume":"52","author":"W Chen","year":"2010","unstructured":"Chen, W., Chang, B., Li, L. & Chan, L. Patatin-like phospholipase domain-containing 3\/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 52, 1134\u20131142 (2010).","journal-title":"Hepatology"},{"key":"1680_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","volume":"22","author":"D Lind\u00e9n","year":"2019","unstructured":"Lind\u00e9n, D. et al. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol. Metab. 22, 49\u201361 (2019).","journal-title":"Mol. Metab"},{"key":"1680_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","volume":"15","author":"Y Geng","year":"2021","unstructured":"Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H. & Moshage, H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol. Int. 15, 21\u201335 (2021).","journal-title":"Hepatol. Int."},{"key":"1680_CR40","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","volume":"158","author":"BA Neuschwander-Tetri","year":"2020","unstructured":"Neuschwander-Tetri, B. A. Therapeutic landscape for NAFLD in 2020. Gastroenterology 158, 1984\u20131998 (2020).","journal-title":"Gastroenterology"},{"key":"1680_CR41","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","volume":"3","author":"L Parlati","year":"2021","unstructured":"Parlati, L., R\u00e9gnier, M., Guillou, H. & Postic, C. New targets for NAFLD. JHEP Rep. 3, 100346 (2021).","journal-title":"JHEP Rep."},{"key":"1680_CR42","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1194\/jlr.M020156","volume":"53","author":"J Qi","year":"2012","unstructured":"Qi, J. et al. The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2. J. Lipid Res. 53, 1106\u20131116 (2012).","journal-title":"J. Lipid Res."},{"key":"1680_CR43","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","volume":"33","author":"BL Clifford","year":"2021","unstructured":"Clifford, B. L. et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 33, 1671\u20131684 (2021).","journal-title":"Cell Metab."},{"key":"1680_CR44","doi-asserted-by":"publisher","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","volume":"11","author":"E Henriksson","year":"2020","unstructured":"Henriksson, E. & Andersen, B. FGF19 and FGF21 for the treatment of NASH\u2014two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human. Front. Endocrinol. (Lausanne) 11, 601349 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"1680_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","volume":"73","author":"S Lefere","year":"2020","unstructured":"Lefere, S. et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J. Hepatol. 73, 757\u2013770 (2020).","journal-title":"J. Hepatol."},{"key":"1680_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12944-017-0473-y","volume":"16","author":"H Itabe","year":"2017","unstructured":"Itabe, H., Yamaguchi, T., Nimura, S. & Sasabe, N. Perilipins: a diversity of intracellular lipid droplet proteins. Lipids Health Dis. 16, 83 (2017).","journal-title":"Lipids Health Dis."},{"key":"1680_CR47","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","volume":"26","author":"C-W Kim","year":"2017","unstructured":"Kim, C.-W. et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench Investigation. Cell Metab. 26, 394\u2013406 (2017).","journal-title":"Cell Metab."},{"key":"1680_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217\u2013225 (2005).","journal-title":"Cell Metab."},{"key":"1680_CR49","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","volume":"19","author":"ET Sawey","year":"2011","unstructured":"Sawey, E. T. et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347\u2013358 (2011).","journal-title":"Cancer Cell"},{"key":"1680_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1439-8","volume":"19","author":"FWB Sanders","year":"2018","unstructured":"Sanders, F. W. B. et al. Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption. Genome Biol. 19, 79 (2018).","journal-title":"Genome Biol."},{"key":"1680_CR51","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1172\/JCI118645","volume":"97","author":"LC Hudgins","year":"1996","unstructured":"Hudgins, L. C. et al. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J. Clin. Invest. 97, 2081\u20132091 (1996).","journal-title":"J. Clin. Invest."},{"key":"1680_CR52","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","volume":"146","author":"JE Lambert","year":"2014","unstructured":"Lambert, J. E., Ramos\u2013Roman, M. A., Browning, J. D. & Parks, E. J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726\u2013735 (2014).","journal-title":"Gastroenterology"},{"key":"1680_CR53","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","volume":"38","author":"A Lonardo","year":"2021","unstructured":"Lonardo, A., Arab, J. P. & Arrese, M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Adv. Ther. 38, 2130\u20132158 (2021).","journal-title":"Adv. Ther."},{"key":"1680_CR54","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/1873-3468.14134","volume":"595","author":"Y Hayashi","year":"2021","unstructured":"Hayashi, Y. et al. Ablation of fatty acid desaturase 2 (FADS2) exacerbates hepatic triacylglycerol and cholesterol accumulation in polyunsaturated fatty acid\u2010depleted mice. FEBS Lett. 595, 1920\u20131932 (2021).","journal-title":"FEBS Lett."},{"key":"1680_CR55","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/gutjnl-2012-303179","volume":"63","author":"C L\u00f3pez-Vicario","year":"2014","unstructured":"L\u00f3pez-Vicario, C. et al. Molecular interplay between \u03945\/\u03946 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut 63, 344\u2013355 (2014).","journal-title":"Gut"},{"key":"1680_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/embr.201338041","volume":"15","author":"W Stoffel","year":"2014","unstructured":"Stoffel, W. et al. Obesity resistance and deregulation of lipogenesis in \u03946\u2010fatty acid desaturase (FADS2) deficiency. EMBO Rep. 15, 110\u2013120 (2014).","journal-title":"EMBO Rep."},{"key":"1680_CR57","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","volume":"18","author":"H Yki-J\u00e4rvinen","year":"2021","unstructured":"Yki-J\u00e4rvinen, H., Luukkonen, P. K., Hodson, L. & Moore, J. B. Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 18, 770\u2013786 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1680_CR58","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2337\/db08-1074","volume":"58","author":"A Kotronen","year":"2009","unstructured":"Kotronen, A. et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58, 203\u2013208 (2009).","journal-title":"Diabetes"},{"key":"1680_CR59","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3945\/ajcn.111.030114","volume":"95","author":"H Bjermo","year":"2012","unstructured":"Bjermo, H. et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am. J. Clin. Nutr. 95, 1003\u20131012 (2012).","journal-title":"Am. J. Clin. Nutr."},{"key":"1680_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ng.291","volume":"41","author":"S Kathiresan","year":"2009","unstructured":"Kathiresan, S. et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41, 56\u201365 (2009).","journal-title":"Nat. Genet."},{"key":"1680_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ng.269","volume":"41","author":"YS Aulchenko","year":"2009","unstructured":"Aulchenko, Y. S. et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41, 47\u201355 (2009).","journal-title":"Nat. Genet."},{"key":"1680_CR62","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","volume":"54","author":"M Vujkovic","year":"2022","unstructured":"Vujkovic, M. et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat. Genet. 54, 761\u2013771 (2022).","journal-title":"Nat. Genet."},{"key":"1680_CR63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","volume":"8","author":"WP Esler","year":"2019","unstructured":"Esler, W. P. & Bence, K. K. Metabolic targets in nonalcoholic fatty liver disease. Cell. Mol. Gastroenterol. Hepatol. 8, 247\u2013267 (2019).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"1680_CR64","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/cells9040964","volume":"9","author":"T Hurrell","year":"2020","unstructured":"Hurrell, T. et al. Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis. Cells 9, 964 (2020).","journal-title":"Cells"},{"key":"1680_CR65","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"1680_CR66","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41551-020-00622-8","volume":"5","author":"RD Chow","year":"2021","unstructured":"Chow, R. D., Chen, J. S., Shen, J. & Chen, S. A web tool for the design of prime-editing guide RNAs. Nat. Biomed. Eng. 5, 190\u2013194 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1680_CR67","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1139\/y59-099","volume":"37","author":"EG Bligh","year":"1959","unstructured":"Bligh, E. G. & Dyer, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911\u2013917 (1959).","journal-title":"Can. J. Biochem. Physiol."},{"key":"1680_CR68","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nmeth.3393","volume":"12","author":"H Tsugawa","year":"2015","unstructured":"Tsugawa, H. et al. MS-DIAL: data-independent MS\/MS deconvolution for comprehensive metabolome analysis. Nat. Methods 12, 523\u2013526 (2015).","journal-title":"Nat. Methods"}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-023-01680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-023-01680-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-023-01680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:05:52Z","timestamp":1699574752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-023-01680-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1038\/s41587-023-01680-4","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.C. is inventor of several patents related to organoid technology; his full disclosure is given at . D.H., B.A. and H.C. are inventors on a filed patent application related to this work (PCT\/NL2022\/050641). Near the end of this study, H.C. became head of Pharma, Research and Early Development of F. Hoffmann-La Roche Ltd, Basel, Switzerland. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}